Dec 122023 FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks As Vertex and CRISPR Therapeutics’ exa-cel and Verve Therapeutics’ VERVE-101 move forward, questions remain about possible drawbacks of such therapies.
